RADNOR, Pa. ,
June 21,
2024 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a
leading global provider of mission-critical products and services
to customers in the life sciences and advanced technologies
industries, today announced that Corey
Walker has rejoined the company as President of Avantor's
Laboratory Solutions business, reporting to CEO Michael Stubblefield.
"Corey's deep knowledge of our end markets and industry, coupled
with his familiarity with our organization and customers, makes him
the ideal leader for our Laboratory Solutions business," said
Michael Stubblefield, President and
Chief Executive Officer. "We are very excited to welcome Corey back
to Avantor to advance our business transformation and accelerate
our growth strategy."
Mr. Walker has a track record of success and deep expertise in
life sciences, advanced technologies and applied materials. Most
recently, he was Chief Executive Officer of ILC Dover, a global
supplier to the biopharma and medical device end markets. From 2016
to 2020, he was an Executive Vice President at Avantor and led the
Americas region as well as the global Biomaterials and Electronic
Materials businesses. He holds a bachelor's in marketing and
business management from Brigham Young
University, and an MBA from Harvard
Business School.
Added Corey Walker, President of
Laboratory Solutions: "Avantor has established an enviable market
position, portfolio and value proposition. I have always had great
respect for Michael and the company, and I look forward to
partnering with the team to enhance the customer experience,
accelerate our transformation and drive growth."
Mr. Walker succeeds Randy Stone,
who served as Executive Vice President of Laboratory Solutions.
"We appreciate Randy's contributions to Avantor, including
leading a best-in-class Laboratory Solutions segment team and
advancing our business transformation, and we wish him continued
success," added Stubblefield.
Avantor's new operating model, including two global operating
segments – Laboratory Solutions and Bioscience Production – became
effective in January 2024. The
company is reaffirming fiscal year 2024 guidance, as last
reaffirmed during its first quarter earnings call.
About Avantor
Avantor® is a leading life
science tools company and global provider of mission-critical
products and services to the life sciences and advanced technology
industries. We work side-by-side with customers at every step of
the scientific journey to enable breakthroughs in medicine,
healthcare, and technology. Our portfolio is used in virtually
every stage of the most important research, development and
production activities at more than 300,000 customer locations in
180 countries. For more information, visit avantorsciences.com and
find us on LinkedIn, Twitter and Facebook.
Forward-Looking and Cautionary Statements
This press
release contains forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934, which are subject to the safe
harbor created thereby under the Private Securities Litigation
Reform Act of 1995. All statements other than statements of
historical fact included in this press release are forward-looking
statements. Forward-looking statements discuss our current
expectations and projections relating to our financial condition,
results of operations, plans, objectives, future performance and
business. These statements may be preceded by, followed by or
include the words "aim," "anticipate," "assumption," "believe,"
"continue," "estimate," "expect," "forecast," "goal," "guidance,"
"intend," "likely," "long-term," "near-term," "objective,"
"opportunity," "outlook," "plan," "potential," "project,"
"projection," "prospects," "seek," "target," "trend," "can,"
"could," "may," "should," "would," "will," the negatives thereof
and other words and terms of similar meaning.
Forward-looking statements are inherently subject to risks,
uncertainties and assumptions; they are not guarantees of
performance. You should not place undue reliance on these
statements. We have based these forward-looking statements on our
current expectations and projections about future events. Although
we believe that our assumptions made in connection with the
forward-looking statements are reasonable, we cannot assure you
that the assumptions and expectations will prove to be correct.
Factors that could contribute to these risks, uncertainties and
assumptions include, but are not limited to, the factors described
in "Risk Factors" in our most recent Annual Report on Form 10-K, as
such risk factors may be updated from time to time in our periodic
filings with the SEC.
All forward-looking statements attributable to us or persons
acting on our behalf are expressly qualified in their entirety by
the foregoing cautionary statements. In addition, all
forward-looking statements speak only as of the date of this press
release. We undertake no obligations to update or revise publicly
any forward-looking statements, whether as a result of new
information, future events or otherwise other than as required
under the federal securities laws.
Investor Relations Contact
Christina Jones
Vice President, Investor Relations
Avantor
805-617-5297
Christina.Jones@avantorsciences.com
Global Media Contact
Emily
Collins
Vice President, External Communications
Avantor
332-239-3910
Emily.Collins@avantorsciences.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/avantor-appoints-corey-walker-as-president-of-laboratory-solutions-302179030.html
SOURCE Avantor and Financial News